ArticlePloS one2025
Incidence and progression of diabetic retinopathy and blindness in Indonesian adults with type 2 diabetes.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo report the incidence and progression rate of diabetic retinopathy (DR) and blindness in Indonesian adults with type 2 diabetes.
methodsThis was a prospective cohort study of 899 adults aged >30 years with confirmed type 2 diabetes. All participants underwent standardized clinical and eye examinations. Two-field retinal photographs were taken. DR was graded by trained grader masked to participants' clinical details. We categorized DR as follows: mild, moderate, severe non-proliferative (NPDR), and proliferative DR (PDR). Additional category of vision-threatening DR (VTDR) included severe NPDR or more, or moderate NPDR with clinically significant macular edema. Blindness was defined as visual acuity ≤3/60. At least 1-step progression was categorized as DR progressing. Cox-proportional hazard model was used.
resultsThe incidence and progression of DR were 34.6 and 35.1, and incidence of VTDR and blindness were 24.5 and 8.33/1000 person-years, respectively. Longer diabetes duration was associated with increasing the risk of developing DR (Hazard ratio 1.37 [95% confidence interval 1.10-1.72]) and VTDR (2.00 [1.60-2.50]) and progressing DR (1.50 [1.23-1.84]) in 5 years. Obesity was associated with increased risk of developing DR (1.75 [1.14-2.68]) and the presence of gangrene (2.54 [1.49-4.35]) and neuropathy (1.50 [1.07-2.10]) at baseline increased the risk of progressing DR in 5 years. Living in rural area was associated with increased risk of blindness (2.50 [1.03-5.88]).
conclusionsWe reported the incidence and progression rate of DR, VTDR, and blindness, and documented that longer diabetes duration increased the risk of DR and VTDR in 5 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.